AbbVie (ABBV) +4.6% after Morgan Stanley analyst David Risinger upgrades the stock to...

|About: AbbVie Inc. (ABBV)|By:, SA News Editor

AbbVie (ABBV) +4.6% after Morgan Stanley analyst David Risinger upgrades the stock to "Overweight," citing the company's "under-appreciated pipeline" and other factors. Risinger reckons AbbVie can grab at least 20% of the growing hepatitis C market, and while the analyst maintains his 2013 estimates for the company, he boosts his 2020 EPS forecast to $4.61 from a prior prediction of $2.96.